Semaglutide, a once-weekly GLP-1 receptor agonist, has emerged as an effective therapeutic for its marked weight reduction and cardiometabolic benefits, including reductions in visceral adipose tissue 3,4,5
Studies with aged mice demonstrated several improvements, including restoration of fur density, improved kidney function, increased physical activity (including running), and overall improvements in age-related frailty markers
GLP-1 Use Cases and Barriers to Entry The primary use case for GLP-1 medications is shifting
Early clinical trials show weight loss exceeding 24% of body weight, surpassing even tirzepatide
How Often Do You Actually Need Blood Tests on GLP-1 Medications